ERBB2 and gastric cancer: A gastric cancer dose toxicity study, which included patients with low HER2 expression gastric cancer, showed significant anti-tumor activity in a phase I pilot study, thus suggesting the potential efficacy of this therapy in patients with low HER2 expression gastric cancer (32).